Tags

Type your tag names separated by a space and hit enter

Failure of intralesional propranolol in infantile hemangiomas.
Pediatr Dermatol 2014 Mar-Apr; 31(2):156-8PD

Abstract

The purpose of this study was to evaluate the use of intralesional propranolol injection in the management of small, noncomplicated infantile hemangiomas (IHs) located in areas of cosmetic concern. A prospective study was performed in six female infants with small, non-complicated IHs in areas of cosmetic concern. The parents had refused oral propranolol or the patients had no response to topical timolol or had relapsed after oral propranolol and the parents refused further systemic treatment. All six patients were treated with 1 mg/mL propranolol solution at a dose of 0.2 mL/cm(2). The size, color, and growth of the hemangiomas were monitored and recorded every 4 weeks. Treatment response was evaluated using a 5-point scale: much better (+2), better (+1), same (0), worse (-1), and much worse (-2). Heart rate and blood pressure were measured before and 1 hour after each injection. Adverse effects after medication were evaluated and managed accordingly. All hemangiomas stopped growing during therapy, but no significant changes in size or color were observed, even after repeated injections, and all patients were evaluated as 0 (same). One patient whose hemangioma stopped growing during treatment presented rebound growth after therapy cessation. No changes in heart rate or blood pressure were observed after intralesional propranolol injection. Adverse effects observed were pain and redness after injection. Intralesional propranolol seems safe but is not effective for the treatment of IH.

Authors+Show Affiliations

Pediatric Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24000875

Citation

Torres-Pradilla, Mauricio, and Eulalia Baselga. "Failure of Intralesional Propranolol in Infantile Hemangiomas." Pediatric Dermatology, vol. 31, no. 2, 2014, pp. 156-8.
Torres-Pradilla M, Baselga E. Failure of intralesional propranolol in infantile hemangiomas. Pediatr Dermatol. 2014;31(2):156-8.
Torres-Pradilla, M., & Baselga, E. (2014). Failure of intralesional propranolol in infantile hemangiomas. Pediatric Dermatology, 31(2), pp. 156-8. doi:10.1111/pde.12175.
Torres-Pradilla M, Baselga E. Failure of Intralesional Propranolol in Infantile Hemangiomas. Pediatr Dermatol. 2014;31(2):156-8. PubMed PMID: 24000875.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Failure of intralesional propranolol in infantile hemangiomas. AU - Torres-Pradilla,Mauricio, AU - Baselga,Eulalia, Y1 - 2013/09/03/ PY - 2013/9/5/entrez PY - 2013/9/5/pubmed PY - 2015/1/27/medline SP - 156 EP - 8 JF - Pediatric dermatology JO - Pediatr Dermatol VL - 31 IS - 2 N2 - The purpose of this study was to evaluate the use of intralesional propranolol injection in the management of small, noncomplicated infantile hemangiomas (IHs) located in areas of cosmetic concern. A prospective study was performed in six female infants with small, non-complicated IHs in areas of cosmetic concern. The parents had refused oral propranolol or the patients had no response to topical timolol or had relapsed after oral propranolol and the parents refused further systemic treatment. All six patients were treated with 1 mg/mL propranolol solution at a dose of 0.2 mL/cm(2). The size, color, and growth of the hemangiomas were monitored and recorded every 4 weeks. Treatment response was evaluated using a 5-point scale: much better (+2), better (+1), same (0), worse (-1), and much worse (-2). Heart rate and blood pressure were measured before and 1 hour after each injection. Adverse effects after medication were evaluated and managed accordingly. All hemangiomas stopped growing during therapy, but no significant changes in size or color were observed, even after repeated injections, and all patients were evaluated as 0 (same). One patient whose hemangioma stopped growing during treatment presented rebound growth after therapy cessation. No changes in heart rate or blood pressure were observed after intralesional propranolol injection. Adverse effects observed were pain and redness after injection. Intralesional propranolol seems safe but is not effective for the treatment of IH. SN - 1525-1470 UR - https://www.unboundmedicine.com/medline/citation/24000875/Failure_of_intralesional_propranolol_in_infantile_hemangiomas_ L2 - https://doi.org/10.1111/pde.12175 DB - PRIME DP - Unbound Medicine ER -